Hi. Good morning, everyone. I'm Ellie Merle, one of the biotech analysts here at Barclays. Thank you for joining us here in Sunny Miami. Very happy to have 4D Molecular Therapeutics here with us today ...

4D Molecular Therapeutics, Inc. ( FDMT) TD Cowen 46th Annual Health Care Conference March 3, 2026 10:30 AM EST ...

Treatment-naïve BRVO eyes showed logMAR BCVA improvement (0.64 to 0.41) alongside CRT reduction (527 µm to 285 µm) over short-term follow-up with SB15. Central RVO eyes improved from logMAR 1.29 to 0.

Ophthalmology is the highest volume outpatient specialty within the NHS and the medicines used for medical retinal vascular conditions account for some of the highest cost and volume treatments used ...

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron’s global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 ...

Patients treated with olatorepatide achieved up to 19% body-weight loss at week 48 Regeneron's global Phase 3 registrational program to be initiated later this year TARRYTOWN, N.Y., March 09, 2026 (GL ...

Eyepoint Pharma () has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium. Unlock hedge fund-level data and powerful investing ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...